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Abstract: A new bioactive macrolactone, nuiapolide (1) was identified from a marine 
cyanobacterium collected off the coast of Niihau, near Lehua Rock. The natural product 
exhibits anti-chemotactic activity at concentrations as low as 1.3 μM against Jurkat cells, 
cancerous T lymphocytes, and induces a G2/M phase cell cycle shift. Structural 
characterization of the natural product revealed the compound to be a 40-membered 
macrolactone with nine hydroxyl functional groups and a rare tert-butyl carbinol residue. 
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1. Introduction 
Natural product extracts have long been implemented as therapeutics all over the world, such as 
Mesopotamia, Egypt, India, and China [1–4]. The history of herbal drug use clearly shows the 
significance of natural products as medicines. The natural product’s industry entered into a new era after 
the discovery of penicillin in 1928, which was the first pure antibiotic isolated from the fungus 
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Penicillium rubens [5,6]. Although it took more than ten years for penicillin to be marketed, the 
remarkable success spurred researchers to perform large-scale exploration of other microorganisms. 
Today, this effort continues with at least 50% of all new approved drugs from 1981 to 2010 being a 
natural product or natural product derivative [7]. In recent years, the search for new bioactive compounds 
has also been hastened by the development of high throughput screening (HTS) efforts, which can assess 
more than 250,000 samples per day [8]. 
The ocean covers more than 70% of the Earth’s surface, teeming with bioactive natural products to 
be had from diverse sources as microorganisms, invertebrates, plants, and animals. While natural product 
drug therapeutics have classically come from terrestrial plants and microbes, in the last decade, a variety 
of marine natural products and/or their derivatives have been marketed such as ziconotide (Prialt®, Elan 
Pharmaceuticals, Dublin, Ireland) from a tropical cone snail for the treatment of pain, cytarabine 
(Cystosar-U, Teva Pharmaceuticals, Petah Tikya, Israel) and ecteinascidin 743 (Yondelis®, Pharma Mar 
S.A., Madrid, Spain) for the treatment of cancer, and omega-2-acid ethyl esters (Lovza®, 
GlaxoSmithKline, London, UK) for the treatment of hypertriglyceridemia [9–11]. 
Here, we evaluate marine microbial extracts for their ability to inhibit cellular chemotaxis.  
Cancer cell metastasis is enhanced by chemotaxis, the migration of a cell in response to a chemical 
stimulus [12]. Chemotaxis is observed in almost all organisms, including single-cell and multicellular 
organisms. Single-cell organisms, such as bacteria, approach nutritional chemicals but flee from toxic 
chemicals [13]. Multicellular organisms utilize the phenomenon for single cell functions, such as the 
movement of sperm toward an egg or of immune cells toward their targets [14,15]. The process, 
however, also inevitably enables some cancer cells to migrate from one location to another, triggering 
the development of cancers at the new site. Because many cancers are not visible and do not present 
symptoms until they grow sufficiently large, they may hide in other parts of the body for months or years 
even though the original cancer has been eliminated. Therefore, the identification of a chemical with the 
ability to block chemotaxis of cancer cells could provide an effective strategy for cancer treatment as an 
anti-metastatic agent [16]. Alternatively, compounds with anti-chemotactic behavior, e.g., FTY720 
(fingolimod) can also play a key role in modulating the immune system, thus serving as effective 
immunosuppressive agents [17,18]. 
2. Results and Discussion 
2.1. Evaluation of Hawaiian Marine Natural Product Extracts for Anti-Chemotactic Behavior 
To identify marine natural products with potential anti-metastatic or immunosuppressive activity, 
microorganisms from the Hawaiian waters were collected and assayed. A total of 560 crude extract 
samples were evaluated for their ability to inhibit the chemotactic activity of Jurkat cells in a Boyden 
chamber assay [19]. Jurkats are a human cancerous T lymphocyte cell line that is capable of exhibiting 
migration toward a nutrient source, fetal bovine serum (FBS) [20]. A Boyden chamber is comprised of 
two wells separated by a membrane. The T-cells are added to the top well with fresh culture medium; a 
nutrient source (the chemotactic agent) and the test substance are added to the bottom well. Following 
incubation, the bottom well is analyzed for the presence of cells. Cells will be present in the bottom 
chamber if the test substance does not inhibit the chemotactic activity, but cells will remain in the top 
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chamber if the test substance is active. FTY720, a derivative of the natural product myriocin and an 
approved drug for the treatment of multiple sclerosis (MS), was utilized as a control substance. In vivo, 
FTY720 is phosphorylated to form FTY720-phosphate, which resembles sphingosine 1-phosphate 
(S1P). S1P receptors are expressed on a wide range of cells that play a key role in the immune system 
and the central nervous system (CNS) [17,18]. At higher dosings, FTY720 is also cytotoxic. It has 
demonstrated preclinical antitumor efficacy in several cancer models [21] and has been shown to target 
TRPM7, a receptor linked to metastasis in breast cancer [22]. 
The crude extract samples were assayed at 25 μg/mL, consistent with typical screening concentrations 
for natural product extracts. Following incubation, the cells were visually observed with an inverted 
microscope (Figure 1). Panel (a) represents cells exposed to medium alone (no chemotactic agent) and 
a minimal number of cells were observed in the bottom chamber. When the chemotactic agent fetal 
bovine serum (FBS) was present, Panel (b), a dense lawn of cells was observed. Few cells (a combination 
of live and dead cells) were also observed when cells were exposed to 5 μg/mL FTY720, Panel (c). Panel 
(d) shows cells exposed to sample extract 13-F10, one of 50 samples that gave a positive result in this 
assay; the well showed the presence of a few live cells. 
 
Figure 1. Evaluation of Jurkat cultures in the Boyden chamber assay. Images of microscope 
fields of the bottom well after 24 h of incubation. (a) Bottom well received no FBS and no 
test substance; (b) Bottom well received 10% FBS and no test substance; (c) Bottom well 
received 10% FBS and FTY720 (5 µg/mL); (d) Bottom well received 10% FBS and 13-F10 
extract (25 µg/mL). Shrinkage of cells in (c) is indicative of cell death. 
2.2. Cytotoxicity Assay for Active Crude Extracts 
An ideal natural product with anti-metastatic potential would be one that inhibits the chemotactic 
activity but is not cytotoxic, as most chemicals that are cytotoxic to cancer cells are also cytotoxic to 
healthy cells. At the same time, cell toxicity alone could explain the observed lack of cell motility. Thus, 
the 50 samples that were shown to inhibit Jurkat cell chemotaxis were subsequently assessed for cellular 
cytotoxicity. After incubation with test substances, the number of live cells was analyzed by microscopy 
and with a CyQUANT® Cell Proliferation Assay Kit. It was shown that seven out of the  
50 samples did not demonstrate significant cytotoxicity against Jurkat cells at a concentration of  
25 μg/mL (Figure 2) as compared to the control (T-cells in the absence of any test substances). 
Cytotoxicity assays were performed at 25 μg/mL as this is the highest dose in which chemotaxis assays 
were performed; compounds of interest would not reveal toxicity at this high concentration. 
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(a) 
(b) 
Figure 2. Cytotoxicity profile analysis of extracts: The turquoise bar represents samples 
where the percentage of live cells is ≥90% of the control. The black bar represents samples 
where the percentage of live cells is <90%. Controls included wells grown without FBS  
(−FBS) and with FTY720 (1 or 5 µg/mL). Sample codes are library plate number and 
coordinate on the plate. (a) Sample set 10- to 15- and (b) sample set 16- and 17-. 
2.3. Evaluation of Fractionated Extracts for Anti-Chemotactic Behavior 
Sample well 13-F10, an extract from a cyanobacterium whose partial 16S gene sequence showed a 
highly significant hit to Okeania plumata, was selected for further evaluation because it showed 
chemotaxis inhibition activity at lower dosage (10 μg/mL), and it did not show cytotoxicity at these 
concentrations (Figure S1). The active sample was extracted with dichloromethane or methanol and each 
extract was fractionated (1 min/fraction) into 24 wells in a 96-well plate. The resulting fraction plates 
(FP1 and FP2, respectively) were examined in the Boyden chamber assay for anti-chemotactic behavior. 
A major active component with a mass of 788.6 ± 0.2 Da (m/z 789.6, compound 1) was identified. 
For additional details on the isolation/fractionation procedure, please see the Supplementary Information 
section and Figures S2–S6. Compound 1 was isolated to purity, its anti-chemotactic activity confirmed, 
and was obtained in sufficient quantities for further analysis (Figures S7 and S8). Nuiapolide (1) showed 
chemotactic activity at concentrations as low as 1 μg/mL (1.3 μM), Figure 3. 
2.4. Cell Cycle Analysis of Nuiapolide (1) 
Jurkat cell cultures treated with nuiapolide (1) were analyzed by flow cytometry to assay for the 
effects on the cell cycle. The population ratio of cells in each phase of the cell cycle was calculated from 
the histogram including: Gap 0 (G0)/Gap 1 (G1), Synthesis (S), and Gap 2 (G2)/Mitosis (M) [23,24]. 
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Figure 3. Evaluation of nuiapolide (1) activity at 1 µg/mL. Images of microscope fields of the bottom 
well after 24 h of incubation. (a) Bottom well received no FBS and no test substance; (b) Bottom well 
received 10% FBS and no test substance; (c) Bottom well received 10% FBS and FTY720 (5 µg/mL); 
(d) Bottom well received 10% FBS and nuiapolide (1) (1 µg/mL). 
Flow cytometry of Jurkat cells exposed to nuiapolide (1) showed a decrease in the population of cells 
in G0/G1 phase (at all the incubation times) in comparison to the control (0 h). In contrast, S phase cell 
populations increased with shorter exposure times (2–4 h) with cells progressing in G2/M with longer 
exposure to the agent (6 h, Figure 4 and Figure S9). We did not observe any 8N cells; the cell cycle is 
perturbed where there is a slowing or block in G2/M. 
 
Figure 4. Cell cycle analysis of Jurkat cells treated with nuiapolide (1), 5 μg/mL.  
(a) Histograms of Jurkat cells stained with propidium iodide (numbers in the legend indicate 
the number of cells plotted for each treatment); (b) Table providing the % of cells distributed 
in each stage of the cell cycle. 
2.5. Structural Analysis of Nuiapolide (1) 
The molecular formula of nuiapolide (1) was established as C44H84O11 based on HRMS (m/z [M + H]+ 
789.6076, calcd for C44H85O11, 789.6092; [M + Na]+ 811.5895, calcd for C44H84O11Na, 811.5911) and 
requires three degrees of unsaturation. The structure was elucidated by 1H NMR, 13C NMR, 13C NMR 
DEPT, COSY, TOCSY, HSQC, HSQC-TOCSY, in methanol-d4 and DMSO-d6 (Figure 6, Table 1, and 
SI NMR spectra). 13C NMR showed 15 distinct signals, some of which (δC 20.8–21.5, 36.2–37.4, and 
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69.8–70.8) were overlapped with multiple peaks. HSQC correlation paired the 1H and 13C NMR signals. 
C-40 at δC 33.91, C-1 at δC 166.90, and C-3 at δC 161.20, which were absent in the HSQC correlation 
and DEPT, were predicted as R4C for C-40 and a substituted alkene or carbonyl carbon for C-1 and C-3. 
In HMBC, C-40 correlated with H-41-43 (δH 0.93) and H-39 (δH 5.02). As nine protons were predicted 
to be at H-41-43, C-40 and C-41-43 are due to a tert-butyl group attached to C-39. Based on the chemical 
shift and HMBC correlation between H-39 and C-1, C-39 and C-1 were assigned as an α-carbon on an 
oxygen linkage and carbonyl carbon, respectively, indicating that the molecule is an ester. C-1 had an 
HMBC correlation with alkene proton H-2. H-2 correlated with C-3, which also exhibited correlations 
with H-4 and H-44. Since H-44 consisted of 3 protons, this gives methyl substitution on the alkene C-3 
on which C-4 extends the carbon chain further. No additional unsaturated carbons or substitutions were 
found except for hydroxyl groups present in the molecule, thus confirming that nuiapolide (1) is a 
macrolactone with an alkene and two side chains located near the ester functional group (Figure 5) and 
nine hydroxyl groups distributed throughout the saturated hydrocarbon ring structure. 
 
Figure 5. Partial structure of nuiapolide (1) with key HMBC correlations. 
Since three distinct signals of protons on hydroxyl carbons were found in the 1H NMR, this signified 
three different environments for these hydroxyl groups. These protons (locations) were indicated as H-a, 
H-b, and H-c at δH 3.78, 3.57, and 3.42, respectively. H-a contains two protons that had TOCSY 
correlations with H-4 and H-b, but they neither had nor shared COSY correlation. This suggested that 
there were at least two carbons between H-a and others. In HSQC-TOCSY, in addition to correlations 
with carbons at δC 36.2–37.4, there was a correlation with C-8 (δC 43.51), which was proposed as the 
carbon between each H-a. H-c consists of one proton correlated with H-39 and H-b in TOCSY but not 
in COSY. H-c and H-39, however, shared a correlation in COSY. These indicated that there is one carbon 
between H-c and H-39 and at least two carbons between H-c and H-b. Six protons in H-b were almost 
identical, thus their positions were likely equally distributed and spread sufficiently not to affect each 
other. Two distinct HSQC-TOCSY correlations with δC 36.2–37.4 and 20.8–21.5 indicated there were 
two isolated environments between each H-b. This confirmed that the hydroxyl groups at H-b appear at 
every four carbons. Because of the ring size, there cannot be more than four carbons between H-b and 
H-a or H-c, indicating there are three carbons between these. 
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Table 1. NMR spectral data for nuiapolide (1) a. 
Position δH (J in Hz) in MeOH-d4 δH (J in Hz) in DMSO-d6 δC in MeOH-d4, Type δC in DMSO-d6, Type TOCSY HSQC-TOCSY b HMBC c 
1 - - 166.90, C 166.04, C    
2 5.74, s 5.67, s 115.73, CH 116.69, CH 4, 44, 41–43 44 1, 3, 4, 44 
3 - - 161.20, C 160.04, C    
4 2.58, m and 2.83, m 2.59, m 32.69, CH2 33.11, CH2 2, Ha, 5, 6, HC f 5 2, 3, 5 
5 1.60, m 1.49, m 23.86, CH2 24.08, CH2 4, H-a, a-OH, HC f  4, C-i, C-iii 
6 (C-i) d 1.49, m 1.31, m 36.2–37.4, CH2 37.2–38.1, CH2 4, H-a, a-OH, HC f  C-i, C-iii 
7 (H-a) e (C-iii) d 3.78, s 3.58, s 69.8–70.8, CH 69.2–70.2, CH 4, a-OH, H-b, HC f C-i, 8  
(7)-OH - 4.44, d (4.4) or 4.47, d (4.2) - - H-a, HC f  8, C-i, C-iii 
8 1.56, m 1.37 43.51, CH2 44.67, CH2 H-a, a-OH, HC f C-i, C-ii, C-iii C-iii 
9 (H-a) e (C-iii) d 3.78, s 3.58 69.8–70.8, CH 69.2–70.2, CH 4, a-OH, H-b, HC f C-i, 8  
(9)-OH - 4.44, d (4.4) or 4.47, d (4.2) - - H-a, HC f  8, C-i, C-iii 
10 (C-i) d 1.48–1.59, m 1.24–1.41, m 36.2–37.4, CH2 37.2–38.1, CH2 H-a, HC f C-i, C-ii, C-iii C-i, C-ii, C-iii 
11 (C-ii) d 1.31–1.55, m 1.19–1.37, m 20.8–21.5, CH2 21.4–22.0, CH2 H-b, HC f C-i, C-ii, C-iii C-i, C-iii 
12 (C-i) d 1.48–1.59, m 1.24–1.41, m 36.2–37.4, CH2 37.2–38.1, CH2 H-b, HC f C-i, C-ii, C-iii C-i, C-ii, C-iii 
13 (H-b) e (C-iii) d 3.57, s 3.37, s 69.8–70.8, CH 69.2–70.2, CH H-a, H-c, HC f C-i, C-ii  
(13)-OH - 4.14, d (4.1) - - H-b, HC f  C-i, C-iii 
14 (C-i) c 1.48–1.59, m 1.24–1.41, m 36.2–37.4, CH2 37.2–38.1, CH2 H-b, HC f C-i, C-ii, C-iii C-i, C-ii, C-iii 
15 (C-ii) d 1.31–1.55, m 1.19–1.37, m 20.8–21.5, CH2 21.4–22.0, CH2 H-b, HC f C-i, C-ii, C-iii C-i, C-iii 
16 (C-i) d 1.48–1.59, m 1.24–1.41, m 36.2–37.4, CH2 37.2–38.1, CH2 H-b, HC f C-i, C-ii, C-iii C-i, C-ii, C-iii 
17 (H-b) e (C-iii) d 3.57, s 3.37, s 69.8–70.8, CH 69.2–70.2 H-a, H-c, HC f C-i, C-ii  
(17)-OH - 4.14, d (4.1) - - H-b, HC f  C-i, C-iii 
18 (C-i) d 1.48–1.59, m 1.24–1.41, m 36.2–37.4, CH2 37.2–38.1, CH2 H-b, HC f C-i, C-ii, C-iii C-i, C-ii, C-iii 
19 (C-ii) d 1.31–1.55, m 1.19–1.37, m 20.8–21.5, CH2 21.4–22.0, CH2 H-b, HC f C-i, C-ii, C-iii C-i, C-iii 
20 (C-i) c 1.48–1.59, m 1.24–1.41, m 36.2–37.4, CH2 37.2–38.1, CH2 H-b, HC f C-i, C-ii, C-iii C-i, C-ii, C-iii 
21 (H-b) e (C-iii) d 3.57, s 3.37, s 69.8–70.8, CH 69.2–70.2, CH H-a, H-c, HC f C-i, C-ii  
(21)-OH - 4.14, d (4.1) - - H-b, HC f  C-i, C-ii 
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Table 1. Cont. 
22 (C-i) d 1.48–1.59, m 1.24–1.41, m 36.2–37.4, CH2 37.2–38.1, CH2 H-b, HC f C-i, C-ii, C-iii C-i, C-ii, C-iii 
23 (C-ii) d 1.31–1.55, m 1.19–1.37, m 20.8–21.5, CH2 21.4–22.0, CH2 H-b, HC f C-i, C-ii, C-iii C-i, C-iii 
24 (C-i) d 1.48–1.59, m 1.24–1.41, m 36.2–37.4, CH2 37.2–38.1, CH2 H-b, HC f C-i, C-ii, C-iii C-i, C-ii, C-iii 
25 (H-b) e (C-iii) d 3.57, s 3.37, s 69.8–70.8, CH 69.2–70.2, CH H-a, H-c, HC f C-i, C-ii  
(25)-OH - 4.14, d (4.1) - - H-b, HC f  C-i, C-iii 
26 (C-i) d 1.48–1.59, m 1.24–1.41, m 36.2–37.4, CH2 37.2–38.1, CH2 H-b, HC f C-i, C-ii, C-iii C-i, C-ii, C-iii 
27 (C-ii)d 1.31–1.55, m 1.19–1.37, m 20.8–21.5, CH2 21.4–22.0, CH2 H-b, HC f C-i, C-ii, C-iii C-i, C-iii 
28 (C-i) d 1.48–1.59, m 1.24–1.41, m 36.2–37.4, CH2 37.2–38.1, CH2 H-b, HC f C-i, C-ii, C-iii C-i, C-ii, C-iii 
29 (H-b) e (C-iii) d 3.57, s 3.37, s 69.8–70.8, CH 69.2–70.2, CH H-a, H-c, HC f C-i, C-ii  
(29)-OH - 4.14, d (4.1) - - H-b, HC f  C-i, C-iii 
30 (C-i) d 1.48–1.59, m 1.24–1.41, m 36.2–37.4, CH2 37.2–38.1, CH2 H-b, HC f C-i, C-ii, C-iii C-i, C-ii, C-iii 
31 (C-ii) d 1.31–1.55, m 1.19–1.37, m 20.8–21.5, CH2 21.4–22.0, CH2 H-b, HC f C-i, C-ii, C-iii C-i, C-iii 
32 (C-i) d 1.48–1.59, m 1.24–1.41, m 36.2–37.4, CH2 37.2–38.1, CH2 H-b, HC f C-i, C-ii, C-iii C-i, C-ii, C-iii 
33 (H-b) e (C-iii) d 3.57, s 3.37, s 69.8–70.8, CH 69.2–70.2, CH H-a, H-c, HC f C-i, C-ii  
(33)-OH - 4.14. d (4.1) - - H-b, HC f  C-i, C-iii 
34 (C-i) d 1.48–1.59, m 1.24–1.41, m 36.2–37.4, CH2 37.2–38.1, CH2 H-b, HC f C-i, C-ii, C-iii C-i, C-ii, C-iii 
35 (C-ii) d 1.31–1.55, m 1.19–1.37, m 20.8–21.5, CH2 21.4–22.0, CH2 H-b, HC f C-i, C-ii, C-iii C-i, C-iii 
36 (C-i) d 1.42, m 1.28, m 36.2–37.4, CH2 37.2–38.1, CH2 H-b, HC f 37, C-i, C-ii, C-iii C-i, C-ii, C-iii 
37 (H-c) e 3.42, m 3.25, m 67.58, CH 67.25, CH H-b, c-OH, 39 C-i  
(37)-OH - 4.15, d (5.58) - - 39, H-b, HC f  38, C-i, C-iii 
38 1.58, m 1.44, m 37.55, CH2 38.56, CH2 H-c, c-OH, HC f 37, 39 C-i, C-iii 
39 5.02, dd (9.7, 2.5) 4.94, dd (9.7, 2.5) 76.82, CH 76.91, CH H-c, c-OH, 41–43, 44, HC f 38 1, 37, 38, 40, 41–43 
40 - - 33.91, C 34.60, C    
41–43 0.93, s 0.85, s 25.00, CH3 26.27, CH3 2, 39  39, 40 
44 1.96, s 1.87, s 23.89, CH3 24.91, CH3 39 2, 5 2, 3, 4 
a 1H NMR and 13C NMR in methanol-d4 and DMSO-d6 in the left four columns and 2D NMR correlations in the right four columns for each position were shown on the table; b HSQC-TOCSY correlations are 1H → 13C, 
and correlations at the same position are excluded; c HMBC correlations are 1H → 13C; d Three grouped 13C NMR peaks are marked as C-i, C-ii, and C-iii; e Three 1H NMR peaks of protons on hydroxyl carbons are 
marked as H-a, H-b, and H-c; f HC is overlapped hydrocarbon peaks at 1.31–1.59 (methanol-d4) and 1.19–1.41 (DMSO-d6) in 1H NMR. 
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The proposed location of hydroxyl groups was confirmed by the number of carbons in environments 
through the ring structure (Figure S10). Nine hydroxyl carbons were found at δC 67.58 (C-37) and δC 
69.8–70.8 (C-7, C-9, C-13, C-17, C-21, C-25, C-29, and C-33). There were 16 α-carbons of hydroxyl 
groups (except for C-8) at δC 37.55 (C-38) and 36.2–37.4 (C-6, C-10, C-12, C-14, C-16, C-18, C-20,  
C-22, C-24, C-26, C-28, C-30, C-32, C-34, and C-36). Seven β-carbons (except for C-5) were located at 
δC 20.8–21.5 (C-11, C-15, C-19, C-23, C-27, C-31, and C-35). The location of hydroxyl groups was 
further confirmed by 1H NMR, 13C NMR, COSY, TOCSY, and HMBC in DMSO-d6, which showed 
signals of hydroxyl protons (Table 1 and SI NMR spectra). The new peaks appeared at δH 4.14, 4.15, 
4.44, and 4.47. COSY correlations showed that the peaks at δH 4.44 and 4.47 were from hydroxyl groups 
at position H-a, the peak at δH 4.14 was from H-b hydroxyl groups, and the peak at δH 4.15 was from 
position H-c, which was confirmed by a TOCSY correlation with H-39. HMBC showed correlations 
between δH 4.44/4.47 and C-8, between δH 4.14 and δC 36.2–37.4/69.8–70.8, and between δH 4.15 and 
C-38. Based on the above analyses, the structure of nuiapolide (1) was determined, as shown in Figure 6. 
 
Figure 6. Structure of nuiapolide (1) and caylobolides A (2) and B (3). 
The structure suggested that the compound belongs to the polyketide class of natural products  
and displays structural similarity to the caylobolides, which were shown to be cytotoxic against some 
cancer cell lines [25,26]. Nuiapolide (1) and caylobolides A (2) and B (3) share the core structure of  
a macro-lactone. They contain a large saturated carbohydrate ring with several hydroxyl groups and 
similar side chains around the ester functional group. The number of carbons in the ring structure, 
however, was slightly greater in compound 1 (39 carbons) than in caylobolides (35 carbons). Given the 
structure of 1 and its Hawaiian origins, we named it nuiapolide (1). Nuiapo means big circle in Hawaiian 
and “ide” indicates the macrolide. 
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3. Materials and Methods 
3.1. General Experimental Procedures 
High resolution ESI-MS spectra were measured on an Agilent 6530 QTOF mass spectrometer with 
an Agilent 1200 HPLC system. Unit-resolution ESI-MS spectra were performed on a Thermo Finnigan 
LCQ Deca XP Max ion trap mass spectrometer using ESI ionization interfaced with an Agilent  
1100 HPLC, Thermo Finnigan Surveyor photodiode array (PDA) detector, and a SEDEX 75 Evaporative 
light scattering detector (ELSD). Preparative HPLC was performed using an Agilent 1100 binary 
preparative system with an Agilent multi-wavelength UV detector. An inverted microscope (VWR, 
Radnor, PA, USA) was used for evaluation of Jurkat cells. Photographs of the cells were taken with 
100× magnification (10× ocular and 10× objective lens) and a camera (Olympus, Shinjuku, Tokyo, 
Japan) equipped with a modified lens piece, which fits over the microscope eyepiece. Cell cycle analysis 
of Jurkat cells was performed with a flow cytometer (FACSCalibur, BD Biosciences, San Jose, CA, 
USA). Flow cytometric data were analyzed using ModFitLT (Verity Software House, Topsham, ME, 
USA) and plotted using FlowJo (FlowJo LLC, Ashland, OR, USA). NMR spectra were acquired on a 
Bruker Avance III 500 MHz spectrometer equipped with a 5 mm H-C-N cryoprobe (Bruker Corporation, 
Billerica, Massachusetts, USA) at 500 MHz for 1H NMR and 125 MHz for 13C NMR in methanol-d4 or 
DMSO-d6. 
3.2. Reagents and Chemicals 
Jurkat clone E6-1, its culture medium RPMI 1640, and fetal bovine serum (FBS) were purchased 
from American Type Culture Collection (ATCC, Manassas, VA, USA). Triton X-100, DNase-free 
RNase, propidium iodide, and ampules of NMR solvents (methanol-d4 and DMSO-d6) were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). 
3.3. Sample Preparation for Assay Analysis 
The 560 crude extracts were prepared from freeze-dried samples of microorganisms collected from 
near-shore environments in the main Hawaiian Islands. Active sample 13-F10, was prepared from  
a colonial cyanobacterium (071905-NII-01). Specifically, the freeze-dried cyanobacterium sample  
(105 mg) was extracted in H2O (10 mL) with sonication. The water extracted was filtered and loaded on 
a C-4 solid phase extraction (SPE) cartridge (500 mg, 300 Å). The cartridge was washed with H2O  
(10 mL) and the H2O wash was discarded. The column was then eluted with methanol/water mixtures 
(33:67, 67:33, and 100:0; 6 mL each). The combined fractions were dried under vacuum (3.9 mg) and 
added to our extract libraries as 13-F10. Prior to assay, a small portion of the extract was dissolved in 
methanol/ethyl acetate/t-butyl methyl ether (60:30:10) (MET) and transferred to a 96-well plate.  
The plates were stored desiccated and vacuum packed at −20 °C. Each 96-well plate of extracts was 
solubilized in MET and evaluated in our chemotaxis transwell assay. 
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3.3.1. Details on Cyanobacteria Biomass 
Colonies of the red filamentous cyanobacterium were collected by hand on July 19, 2005 at a depth 
of 12–20 m in waters adjacent to Lehua Rock, an islet off the east shore of Niihau, Hawaii. Samples 
were kept on ice in the field before freezing at −15 °C. The frozen samples were then freeze-dried.  
A dried voucher specimen (071905-NII-01) is deposited in the Department of Natural Sciences, Hawaii 
Pacific University and a partial 16S rRNA gene sequence was deposited in the NCBI GenBank under 
the Accession No. (KT852581). 
3.3.2. DNA Extraction and Sequencing 
DNA was extracted using a Qiagen DNeasy kit. A small portion of frozen biomass was thawed and 
warmed to 55 °C. Lysis buffer (“ATL” buffer, 180 μL) and proteinase K solution (600 mAU/mL;  
20 μL) were added, and the mixture was vortexed, then incubated overnight a 55 °C. After warming the 
mixture to 70 °C, the sample was again vortexted, and chaotropic “AL” buffer (200 μL) was added, 
followed by a 10 min incubation. The sample was then mixed thoroughly with ethanol (200 μL) and 
pipetted into the DNeasy mini-spin column, which was placed in a collection tube and centrifuged at 
6000 g for 1 min. The column was washed by centrifuging again at 6000 g for 1 min after adding the 
chaotropic elution buffer “AW1” (500 μL) and again with wash buffer “AW2” (500 μL) and centrifuging 
again at 20,000 g for 3 min. Elution buffer “AE” (100 μL) was added and incubated at room temperature 
for 1 min, before centrifuging at 6000 g for 1 min. The DNA eluate was collected and stored at −20 °C. 
Primers were developed by Nubel and coworkers (1997) to amplify an approximate 700 bp region of 
16S that allows the specific amplification of cyanobacterial 16S genes sequences [27]. The partial 
sequencing of 16S was accomplished by adding 1 μL of thawed isolated DNA to a mixture of H2O  
(26 μL), dNTP (1.0 μL, Eppendorf, Hamburg, Germany), forward primer (1.0 μL, 20 pmol/μL, 
CYA106F: CGGACGGGTGAGTAACGCGTGA), and reverse primers (1.0 μL, 20 pmol/μL,  
a 1:1 ratio of CYA781Ra: GACTACTGGGGTATCTAATCCCATT and CYA781Rb: 
GACTACAGGGGTATCTAATCCCTTT) in a PCR tube. The mixture was heated to 95 °C for 2 min 
and the following mixture was added: 14.75 μL H2O, 5 μL 10× reaction buffer, and 0.25 μL Taq 
polymerase (Eppendorf, Hamburg, Germany). The following cycles were applied: 10 cycles, 95 °C for 
30 s, 65 °C for 30 s, the cool −1 °C; 30 cycles, 95 °C for 30 s, 55 °C for 30 s, 68 °C for 1 min.  
Finally, the PCR product was held at 68 °C for 7 min and then stored at 4 °C. The PCR product was 
checked for a single correctly sized product by agarose gel electrophoresis, and the band was prepared 
for sequencing using a Qiagen QIAquick spin kit per instructions. Sequencing was conducted by the by 
the Greenwood Molecular Biology Facility (University of Hawaii) employing the ABI Prism BigDye 
Terminator and Primer Cycle Sequencing Chemistries and an ABI 377XL capillary sequencer. 
A tblastx search against the NCBI database with E-value cutoff of ≤1.0 × 10−3 revealed a highly 
significant hit to Okeania plumata (KC986934.1) [28]. 
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3.3.3. Scaled-Up Extraction of the Active Cyanobacterial Species 
For process and storage efficiency, the bulk of our library samples are routinely extracted in organic 
solvents. Sample 071905-NII-01 (5.6 g dry wt) was extracted repeatedly with methanol (65 mL and  
2 × 50 mL) followed by dichloromethane (2 × 50 mL). The methanol extracts were combined and solvent 
was removed under vacuum to yield 1.8 g of extract residue. The dichloromethane extracts were also 
combined and solvent removed under vacuum to yield 34 mg. Analytical amounts of both extracts were 
subject to bioassay-linked fractionation in order to identify the active component(s) of the organism. 
3.3.4. Bioassay-Linked Fractionation of Methanol and Dichloromethane Extracts of the 
Cyanobacterium 071905-NII-01 
Both extracts (dichloromethane, 1.7 mg, FP1; methanol, 2.0 mg, FP2) were fractionated in two  
runs each by reversed-phase HPLC (Phenomenex Luna C18-2 column, 5 μm, 4.6 mm × 250 mm, 
Torrance, CA, USA) using a linear gradient of acetonitrile/water (FP1: 50:50 to 100:0 over 0–15 min, 
then 100% acetonitrile from 15–26 min; FP2: 20:80 to 100:0 over 0–15 min, then 100% acetonitrile from 
15–26 min; flow rate: 1.0 mL/min; UV detection: 200–600 nm). Extract components eluting between 
2.0 and 26.0 min were collected as 60-s fractions into a deep 96-well plate. For each extract, both HPLC 
runs were collected into the same deep-well plate and solvent was removed from the plates under vacuum 
in a centrifugal concentrator at room temperature. Fractions were reconstituted with MET and 
apportioned into low profile 96-well plates for bioassay, averaging 45 and 60 μg/well for FP1 and FP2, 
respectively. Prior to assay, the fractions were reconstituted and diluted in MET and tested as average 
concentrations of 1, 10, and 25 μg/mL. For FP1, the activity concentrated in fractions eluting at 4.0–5.0 
and 12.0–14.0 min. And for FP2, activity concentrated in fractions eluting at 9.0–10.0 and 16.0–17.0 min. 
Taken together, LCMS of both active regions in both fraction plates indicated the presence of the same 
components in each of the two active regions. FP1 fractions had only very minor impurities. The major 
component in the earliest active region for each fraction was absent from adjacent inactive fractions and 
showed a molecular weight of 788.6 (ESI-positive mode m/z 789.6, MH+; ESI-negative mode  
m/z 787.6 [M − H]−). 
3.3.5. Isolation of Nuiapolide (1) 
The major component from the first active fraction in FP1 and FP2 was isolated from the methanol 
extract, guided by LCMS (ESI-positive mode m/z 789.6, MH+; ion trap analyzer). The methanol extract 
(1020 mg) was dissolved in methanol and cleaned up for HPLC by eluting in seven batches from an SPE 
column (C18 silica, 1 g, EM 110167-4) with methanol (17 mL each). The eluate was concentrated under 
vacuum to dryness (996 mg), reconstituted in methanol/water 90:10 (14 mL) and chromatographed in 
seven portions by preparative reversed phase HPLC (Phenomenex Luna C18-2 column, 5 μm,  
22 mm × 250 mm, Torrance, CA, USA; flow rate: 18 mL/min; methanol/water linear gradient 70:30 to 
100:0 from 0–15 min, then 100% methanol from 15–30 min). Peaks were collected based on absorbance 
at 210 nm and analyzed by LCMS. Compound 1, nuiapolide, eluted at 8.6 min (50.7 mg, 0.89% yield, 
dry wt). The purity of nuiapolide (1) (>95%) was determined by LCMS-ELSD analysis (Phenomenex 
Luna C18-2 column, 5 μm, 2 mm × 250 mm, Torrance, CA, USA; flow rate: 0.20 mL/min; 
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acetonitrile/water gradient 50:50 to 100:0 over 0–10 min, then 100% acetonitrile 10–20 min; ELSD  
50 °C; PDA 200–600 nm). 
3.3.6. Structural Analysis of Nuiapolide (1) 
Nuiapolide (1): chartreuse amorphous solid; [α]25D  −12 (CH3OH, c 0.341); 1H and 13C NMR data 
(methanol-d4 and DMSO-d6), see Table 1 and SI figures; HR-TOF-ESIMS, m/z [M + H]+ 789.6076 
(calcd for C44H85O11, 789.6092, ∆ −2.2 ppm), [M + Na]+ 811.5895 (calcd for C44H84O11Na, 811.5911,  
∆ −2.0 ppm). NMR spectra were recorded on a Bruker Avance III. The purified sample (500 μg) was 
dissolved in 500 μL of methanol-d4 or DMSO-d6, which was transferred into a 3 mm NMR sample tube 
(Wilmad LabGlass, Vinelandk, NJ, USA). 1H NMR, 13C NMR, 13C NMR DEPT, COSY, TOCSY, 
HSQC, HSQC-TOCSY, and DMSO-d6 were acquired in methanol-d4 at 298 K (SI figures for spectra; 
Table 1 for assignments), and 1H NMR, 13C NMR, COSY, TOCSY, and HMBC were recorded in 
DMSO-d6 at 315 K (SI figures). 
3.4. Chemotaxis Assay with Jurkat Cells 
Jurkat cells were cultivated in the cell culture medium (RPMI 1640 with 10% FBS) and maintained 
in 75 cm2 culture flasks at 37 °C in 5% CO2. Cells were harvested by centrifugation (10 min at  
1000 rpm), washed twice with the fresh culture medium without serum, and resuspended in fresh culture 
medium. The number of cells was counted with a hemocytometer, and the cell culture volume adjusted 
to give a cell stock solution of 2,000,000 cells/mL. Transwell® (24-well) plates with 5.0 μm permeable 
polycarbonate membrane supports (Boyden chamber, Costar, Corning, NY, USA) were used. The 
bottom well contained 600 μL of cell culture medium with 1, 10, or 25 μg/mL of sample or  
5 μg/mL FTY720, and 100 μL of cells (200,000 cells) was added to the top well. Two controls without 
test samples were utilized to observe cell migration induced by FBS. In the first control, the bottom well 
received MET solution alone. In the second control, fresh RPMI medium without FBS was used for the 
bottom well in order to confirm the enhancement of Jurkat chemotaxis by FBS. After incubation for 24 h, 
the cells were collected from the bottom well to observe how many cells had migrated. 
3.5. Cytotoxicity Assay with Jurkat Cells 
Following 24 h incubation of Jurkat cells in Transwell® plates, as detailed above, the cells were 
transferred to 1.5 mL eppendorf tubes and harvested by centrifugation for 15 min at 14,000 rpm. The 
medium was removed and the cells washed with phosphate buffered saline (PBS) without manganese 
and calcium ions. The resulting cell pellets were frozen in −80 °C for subsequent lysis. Cells were lysed 
and stained with green fluorescent (GR) dye utilizing a CyQUANT® Cell Proliferation Assay Kit 
(Invitrogen, Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA). Samples were 
subsequently transferred into black 96-well plates and analyzed using a 96-well fluorescence plate reader 
to measure relative fluorescence (FLx800 Fluorescence Reader, BioTek, Winooski, VT, USA). 
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3.6. Cell Cycle Analysis by Flow Cytometry 
The effect of nuiapolide (1) on the cell cycle was assessed by flow cytometry. Jurkat cells were 
harvested by centrifugation and counted following the same procedures as detailed in previous  
sections. Cells were added to RPMI cell culture medium in 24-well plates to give a final concentration 
of 400,000 cells/mL, 500 μL total volume. Nuiapolide (1) was added (5.0 μg/mL) and the cells were 
incubated at 37 °C in 5% CO2 for 2, 4, or 6 h. The resulting cells were prepared for flow cytometry 
analysis based on published procedures [29]. Cells were transferred into a 15-mL falcon tube and 
harvested by centrifugation at 1000 rpm for 10 min. Cells were subsequently washed with 5 mL of PBS 
and pelleted at 1000 rpm for 6 min. The supernatant was removed and the cells were resuspended in 0.5 
mL of PBS. The cell suspension was transferred into 4.5 mL of ice-cold ethanol and stored on ice (or 
−20 °C) for more than 2 h. The ethanol fixed cells were collected by centrifugation at 1000 rpm for 5 
min. The cell pellet was resuspended in 5 mL of PBS, incubated for 1 min and centrifuged again at 1000 
rpm for 5 min. The cell pellet was finally resuspended in 1 mL of freshly prepared staining solution 
(PBS, 0.1% of Triton X-100, and 0.2 mg/mL of DNase-free RNase, and 0.02 mg/mL of propidium 
iodide), and incubated at room temperature for 30 min before analyzing the samples by flow cytometry 
using a 488 nm argon laser for excitation and a 585/42 bandwidth filter for fluorescence detection. 
4. Conclusions 
Cell-based screening of marine natural product extracts has led to the discovery of nuiapolide (1) that 
inhibits chemotaxis of Jurkats and induces a predominant G2/M phase shift in the cell cycle. The large,  
40-membered macrolactone contains a rare tert-butyl carbinol residue, which is present in cyanobacterial 
compounds apratoxin A, a cyclodepsipeptide with potent anti-cancer activity, and a couple other 
macrolide compounds, madangolide and laingolide [30–32]. Nuiapolide resembles a previously described 
class of anti-tumor natural products, the caylobolides, which were also isolated from cyanobacteria. 
Caylobolide A and B were isolated from Moorea producens (previously Lyngbya majuscula) and 
Phormidium spp. respectively [25,26]. During the process of publishing this work, bastimolide A, a 
potent anti-malarial compound was reported, as well as amantelide A and B. Both sets of compounds 
were reported from or suspected as Okeania species and represent polyhydroxylated macrolides with a 
tert-butyl carbinol group and may reflect analogs or isomers of nuiapolide (1) [33,34]. 
Given the large molecular structure of nuiapolide (1), further evaluation of this family of compounds 
as anti-metastatic or immunosuppressive agents would greatly benefit from elucidation of the 
biosynthetic gene cluster for bio-engineering purposes or the synthesis of a chemical library of 
compounds based upon a simplified structural motif. 
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